<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bond MJ</submitter><funding>NIH Office of the Director</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>44739-44758</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12851799</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>147(49)</volume><pubmed_abstract>Dysregulated transcription is a defining hallmark of cancer. Recently, novel chemically induced proximity approaches have enabled the rewiring of transcriptional machinery to drive expression of pro-apoptotic genes using bivalent small molecules. In this work, we demonstrate that this strategy is amenable to relocalizing DNA bound transcriptional machinery, such as fusion transcription factors that commonly drive pediatric malignancies. Targeting fusion transcription factors, such as EWSR1::FLI1 in Ewing sarcoma, with these bivalent compounds may open new therapeutic avenues. Here, we develop a small molecule, &lt;b>EB-TCIP&lt;/b>, that recruits FKBP12&lt;sup>F36V&lt;/sup>-tagged EWSR1::FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid chromatin remodeling and expression </pubmed_abstract><journal>Journal of the American Chemical Society</journal><pubmed_title>Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules.</pubmed_title><pmcid>PMC12851799</pmcid><funding_grant_id>F32 CA284750</funding_grant_id><funding_grant_id>1S10OD036228</funding_grant_id><funding_grant_id>R01 CA283395</funding_grant_id><funding_grant_id>S10 OD028697</funding_grant_id><funding_grant_id>R35 CA283977</funding_grant_id><funding_grant_id>T32 GM136631</funding_grant_id><funding_grant_id>U54 CA231637</funding_grant_id><funding_grant_id>S10 OD036228</funding_grant_id><pubmed_authors>Howard B</pubmed_authors><pubmed_authors>Gourisankar S</pubmed_authors><pubmed_authors>Stegmaier K</pubmed_authors><pubmed_authors>Dwyer BG</pubmed_authors><pubmed_authors>Karim BA</pubmed_authors><pubmed_authors>Alexe G</pubmed_authors><pubmed_authors>DiGiovanni G</pubmed_authors><pubmed_authors>Sarott RC</pubmed_authors><pubmed_authors>Jones HM</pubmed_authors><pubmed_authors>Golden RP</pubmed_authors><pubmed_authors>Gray NS</pubmed_authors><pubmed_authors>Ross K</pubmed_authors><pubmed_authors>Bond MJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules.</name><description>Dysregulated transcription is a defining hallmark of cancer. Recently, novel chemically induced proximity approaches have enabled the rewiring of transcriptional machinery to drive expression of pro-apoptotic genes using bivalent small molecules. In this work, we demonstrate that this strategy is amenable to relocalizing DNA bound transcriptional machinery, such as fusion transcription factors that commonly drive pediatric malignancies. Targeting fusion transcription factors, such as EWSR1::FLI1 in Ewing sarcoma, with these bivalent compounds may open new therapeutic avenues. Here, we develop a small molecule, &lt;b>EB-TCIP&lt;/b>, that recruits FKBP12&lt;sup>F36V&lt;/sup>-tagged EWSR1::FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid chromatin remodeling and expression </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-15T13:48:00.652Z</modification><creation>2026-07-05T03:08:40.569Z</creation></dates><accession>S-EPMC12851799</accession><cross_references><pubmed>41307210</pubmed><doi>10.1021/jacs.5c05634</doi></cross_references></HashMap>